InvestorsHub Logo
Followers 829
Posts 119605
Boards Moderated 14
Alias Born 09/05/2002

Re: DewDiligence post# 11445

Thursday, 08/28/2014 12:15:56 PM

Thursday, August 28, 2014 12:15:56 PM

Post# of 20689
BAX’s pharma spin-off (MNTA’s FoB partner) may relocate to Boston (which would facilitate working with MNTA):

http://www.fiercebiotech.com/story/report-big-split-baxter-looks-relocate-biopharma-boston/2014-08-28

For months now rumors of a big prospective biotech relocation have been circulating in the hot Boston hub. And now the Boston Business Journal, a weekly with its ear to the ground on all things related to real estate, reports that its sources are saying that the company in question is Baxter International.

Currently based in Deerfield, IL, Baxter is splitting itself in two, spinning out its biopharma work into a separate company. The BBJ reports that its real estate sources have been looking for 150,000 to 200,000 square feet of space to accomodate Baxter, with another 200,000 square feet of lab space in the second phase of development.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”